指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

难治性革兰阳性菌感染的治疗挑战:新型抗MRSA抗生素左氧氟沙星(静脉)与阿拉左氧氟沙星(口服)治疗作用的共识观点

Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral).
指南 / 共识 · Indian J Med Microbiol · 2024-01-21
一句话结论专家共识支持左氧氟沙星(静脉)与阿拉左氧氟沙星(口服)用于合并多种基础疾病的耐药革兰阳性菌感染,包括MRSA感染。

该共识采用改良德尔菲法,由15名来自内科、重症监护、急诊、微生物学和重症医学的专家对11条预设陈述投票,同意率至少70%即达成共识,最终10条达成共识。共识界定了左氧氟沙星和阿拉左氧氟沙星在耐药革兰阳性病原体(包括MRSA)感染中的治疗作用,适用于存在肾功能障碍或肝病风险或免疫抑制等合并症的患者,以及菌血症、骨与关节感染、糖尿病足感染、发热性中性粒细胞减少和医院获得性肺炎等治疗困难情况。共识支持该药用于需兼具安全性和一致疗效的多种合并症患者的耐药革兰阳性菌感染及某些混合感染。

要点

  • 15名专家对11条预设陈述投票,同意率至少70%即达成共识,最终10条达成共识。
  • 共识支持左氧氟沙星(静脉)和阿拉左氧氟沙星(口服)用于合并症患者的耐药革兰阳性菌感染,包括MRSA。
  • 适用情形包括肾功能障碍或肝病风险或免疫抑制,以及菌血症、骨与关节感染、糖尿病足感染、发热性中性粒细胞减少和医院获得性肺炎。
  • 共识认为该药可用于需兼具安全性和一致疗效的多种合并症患者的耐药革兰阳性菌感染及某些混合感染。
  • 共识由内科、重症监护、急诊、微生物学和重症医学专家参与制定。

适用人群与场景

  • 合并多种基础疾病、需要安全性更好且药代动力学与药效学(PK/PD)特征一致的抗生素的耐药革兰阳性菌感染患者。
  • 存在肾功能障碍或肾功能障碍风险或肝病或免疫抑制的耐药革兰阳性菌感染患者。
  • 革兰阳性菌所致菌血症、骨与关节感染、糖尿病足感染、发热性中性粒细胞减少和医院获得性肺炎患者。

处置流程与药物剂量

  • 共识支持左氧氟沙星(静脉)和阿拉左氧氟沙星(口服)用于治疗耐药革兰阳性菌感染,包括MRSA所致感染及某些混合感染,适用于需兼具安全性和一致疗效的多种合并症患者。

研究设计与关键结果

  • 采用改良德尔菲法,结合证据批判性评价与专家意见,对左氧氟沙星和阿拉左氧氟沙星在不同临床场景及特定未满足需求中的治疗使用进行讨论。
  • 来自内科、重症监护、急诊、微生物学和重症医学的15名专家成员参与,对11条预设陈述投票,同意率至少70%即达成共识。
  • 投票后11条陈述中10条达成共识;共识界定左氧氟沙星和阿拉左氧氟沙星在耐药革兰阳性病原体(包括MRSA)感染中的治疗作用,适用于存在合并症(如肾功能障碍或风险增加或肝病或免疫抑制)的患者,以及菌血症、骨与关节感染、糖尿病足感染、发热性中性粒细胞减少和医院获得性肺炎等治疗困难情况。

证据类型、等级与局限

  • 证据类型:采用改良德尔菲法的专家共识。
  • 达成共识标准:同意率至少70%;11条陈述中10条达成共识。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该共识支持在合并多种基础疾病、需要安全性更好且PK/PD一致的抗生素的耐药革兰阳性菌感染患者中,使用左氧氟沙星(静脉)和阿拉左氧氟沙星(口服)治疗,包括MRSA感染及某些混合感染。
  • 共识支持将该药用于存在肾功能障碍或肾功能障碍风险或肝病或免疫抑制的患者,以及菌血症、骨与关节感染、糖尿病足感染、发热性中性粒细胞减少和医院获得性肺炎等治疗困难情况。

指南或共识出处

  • Indian J Med Microbiol

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Treatment of antibiotic-resistant Gram-positive infections (GPIs), including methicillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly difficult, particularly in patients with multiple co-morbidities who require antibiotics with greater safety and a consistent pharmacokinetic/pharmacodynamic (PK/PD) profile. Such difficult-to-treat GPIs are often associated with poor outcomes, extended hospital stay and increased expenditure. This can be partly attributed to the limited safety and aberrant PK/PD profile of existing anti-MRSA antibiotics. In this context, intravenous levonadifloxacin and its oral prodrug alalevonadifloxacin are novel anti-MRSA antibiotics that have significant advantages over conventional anti-Gram-positive antibiotics. The purpose of this paper was to generate a consensus on the optimal use of levonadifloxacin and alalevonadifloxacin for tackling resistant Gram-positive infections in patients with multiple co-morbidities.

METHOD: Using a modified Delphi approach that combines critical appraisal of evidence and expert opinion, therapeutic use of levonadifloxacin and alalevonadifloxacin in various clinical scenarios and specific unmet conditions was deliberated. Fifteen expert members from medicine, critical-care, emergency, microbiology, and intensive-care disciplines participated and voted on 11 pre-conceived statements. When there was at least 70 % agreement, a consensus was reached.

RESULTS: Following the voting, agreements were reached on 10 out of the 11 statements. Broadly, a consensus was reached in defining the therapeutic role of levonadifloxacin and alalevonadifloxacin in the treatment of various clinical indications involving resistant Gram-positive pathogens, including MRSA, in patients with co-morbidities, such as co-existing or increased risk for kidney dysfunction or hepatic disease and/or immunosuppression; also, in therapeutically challenging conditions caused by Gram-positive bacteria such as bacteraemia, bone and joint infection, diabetic foot infection, febrile neutropenia, and hospital-acquired pneumonia.

CONCLUSIONS: This consensus supports the therapeutic use of levonadifloxacin and alalevonadifloxacin in the treatment of antibiotic-resistant GPIs, including those caused by MRSA and certain polymicrobial infections, in patients with multiple co-morbidities requiring drug with adequate safety and consistent efficacy.

来源:Indian J Med Microbiol,查看原文。版权归原作者所有。

参考来源

  1. Saseedharan S, Dubey D, Singh RK, et al. Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral). Indian J Med Microbiol. 2024. PMID: 38228227. doi:10.1016/j.ijmmb.2024.100528

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。